TOT BIOPHARM International Company Limited (HKG:1875)
Hong Kong · Delayed Price · Currency is HKD 1.900
0.00 (0.00%)
Jul 16, 2025, 3:50 PM HKT
HKG:1875 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| 1,098 | 780.63 | 442.18 | 76.33 | 22.49 | Upgrade | |
Revenue Growth (YoY) | 40.70% | 76.54% | 479.34% | 239.36% | -50.36% | Upgrade |
Cost of Revenue | 315.9 | 206.64 | 71.56 | 48.85 | 6.96 | Upgrade |
Gross Profit | 782.43 | 573.99 | 370.62 | 27.47 | 15.53 | Upgrade |
Selling, General & Admin | 688.09 | 509.33 | 266.54 | 79.19 | 72.81 | Upgrade |
Research & Development | 79.31 | 103.89 | 151.17 | 214.7 | 235.2 | Upgrade |
Other Operating Expenses | -23.12 | -17.88 | -8.76 | -10.95 | -1.05 | Upgrade |
Operating Expenses | 745.32 | 595.03 | 409.55 | 282.93 | 306.96 | Upgrade |
Operating Income | 37.11 | -21.04 | -38.93 | -255.46 | -291.43 | Upgrade |
Interest Expense | -9.88 | -5.18 | -6.6 | -2.47 | -1.71 | Upgrade |
Interest & Investment Income | 3.38 | 2.97 | 2.27 | 0.97 | 1.88 | Upgrade |
Earnings From Equity Investments | - | -2.5 | -6.63 | -0.02 | - | Upgrade |
Currency Exchange Gain (Loss) | -3.97 | 2.26 | 1.3 | 1.24 | 0.32 | Upgrade |
Other Non Operating Income (Expenses) | 9.05 | -11.8 | - | - | - | Upgrade |
EBT Excluding Unusual Items | 35.69 | -35.27 | -48.6 | -255.73 | -290.93 | Upgrade |
Gain (Loss) on Sale of Investments | - | 0.94 | 0.91 | - | 2.21 | Upgrade |
Gain (Loss) on Sale of Assets | -0.93 | -3.42 | -2.36 | -5.49 | 0.22 | Upgrade |
Pretax Income | 34.76 | -37.76 | -50.05 | -261.22 | -288.5 | Upgrade |
Income Tax Expense | - | 0 | - | - | - | Upgrade |
Earnings From Continuing Operations | 34.76 | -37.76 | -50.05 | -261.22 | -288.5 | Upgrade |
Minority Interest in Earnings | - | - | 0.13 | - | - | Upgrade |
Net Income | 34.76 | -37.76 | -49.92 | -261.22 | -288.5 | Upgrade |
Net Income to Common | 34.76 | -37.76 | -49.92 | -261.22 | -288.5 | Upgrade |
Shares Outstanding (Basic) | 725 | 725 | 639 | 573 | 570 | Upgrade |
Shares Outstanding (Diluted) | 725 | 725 | 639 | 573 | 570 | Upgrade |
Shares Change (YoY) | - | 13.44% | 11.50% | 0.53% | 69.92% | Upgrade |
EPS (Basic) | 0.05 | -0.05 | -0.08 | -0.46 | -0.51 | Upgrade |
EPS (Diluted) | 0.05 | -0.05 | -0.08 | -0.46 | -0.51 | Upgrade |
Free Cash Flow | -6.39 | -140.85 | -179.05 | -287.42 | -283.6 | Upgrade |
Free Cash Flow Per Share | -0.01 | -0.19 | -0.28 | -0.50 | -0.50 | Upgrade |
Gross Margin | 71.24% | 73.53% | 83.82% | 36.00% | 69.05% | Upgrade |
Operating Margin | 3.38% | -2.70% | -8.80% | -334.70% | -1295.75% | Upgrade |
Profit Margin | 3.16% | -4.84% | -11.29% | -342.24% | -1282.73% | Upgrade |
Free Cash Flow Margin | -0.58% | -18.04% | -40.49% | -376.57% | -1260.96% | Upgrade |
EBITDA | 98.28 | 17.76 | -4.43 | -224.2 | -262.51 | Upgrade |
EBITDA Margin | 8.95% | 2.27% | -1.00% | -293.75% | - | Upgrade |
D&A For EBITDA | 61.18 | 38.8 | 34.5 | 31.25 | 28.91 | Upgrade |
EBIT | 37.11 | -21.04 | -38.93 | -255.46 | -291.43 | Upgrade |
EBIT Margin | 3.38% | -2.70% | -8.80% | - | - | Upgrade |
Advertising Expenses | 587.12 | 428.46 | 195.93 | 1.22 | 1.36 | Upgrade |
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.